PIN67 Cost-Effectiveness Evaluation Of Amphotericin B, Amphotericin B Liposomal, Caspofungin And Voriconazol In Treating Aspergillosis Under The Brazilian Private Health Care System Perspective  by Fujii, R.K. et al.
 V A L U E  I N  H E A L T H  1 6  ( 2 0 1 3 )  A 1 - A 2 9 8  A91 
 
 
CONCLUSIONS: Quadrivalent seasonal influenza vaccines, at price parity with 
trivalent vaccines, appear to be highly cost-saving from the third-party payer 
and the societal perspectives.  
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OBJECTIVES: Clinical evidence shows that adherence levels ≥90% are required to 
maximize HAART effectiveness on HIV patients. In Mexico, universal access to 
HAART exists; however, average adherence level is 79.8% (95% CI: 77.8-81.8). The 
purpose of this study was to analyze two patient-level reminder interventions 
aimed to increase adherence levels. METHODS: The study design was a cost-
effectiveness analysis from the governmental perspective. All the costs were 
expressed in 2010 constant USD. A natural history of disease dynamic model for 
HIV was used to estimate the following parameters: CD4 and CD8 cell replication 
and mortality rates, as well as infectivity rates of individuals simulated. Also, we 
analyzed data from a national representative survey of HIV patients on HAART 
(N=2289) and presenting at 50 governmental hospital/clinics to obtain adherence 
levels. With these parameters we used a Markov model to estimate life 
expectancy, total patients’ care costs, and therefore cost-effectiveness ratios. 
Patients were classified as adherent (≥90%) and non-adherent (<90%). We 
evaluated two patient-level reminder interventions: (1) three reminder text 
messages (SMS) sent daily to the patient’s cell phone, and (2) a pill reminder. 
Both were modeled throughout the patients’ lives. We performed sensitivity 
analysis for both adherence levels and costs. RESULTS: Of the 2289 patients, 26% 
were adherent (≥90%) (mean adherence level: 79.8%). We did not find statistically 
significant differences between adherents and non-adherents in 
sociodemographic characteristics. Seventy percent reported that HAART daily 
intake omission is the main reason for non-adherence. Interventions increase 
life expectancy by 2.6 years (SMS) and 3.1 years (pill reminder) with an 
incremental cost of $4050 and $5552, respectively. Incremental cost-effectiveness 
ratios are $207 and $637 per year life gained (3% annual discount rate). 
CONCLUSIONS: Both interventions are below one GDP per capita; therefore, they 
are cost-effective and could be considered for implementation in our country.  
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OBJECTIVES: To determine the incremental cost-effectiveness of linezolid versus 
vancomycin using data from a clinical trial assessing treatment of nosocomial 
pneumonia due to MRSA in hospitalized adults. METHODS: A cost-effectiveness 
analysis from the U.S. hospital-payer perspective was piggybacked onto a phase 
4, randomized, double-blind, multicenter trial (Wunderink et al, Clin Infect Dis 
2012) in nosocomial pneumonia patients with culture-proven MRSA 
[microbiologic confirmed intent-to-treat (mITT) cohort]. Efficacy was measured 
by treatment success (defined as Cure+Improvement) at the end of study (i.e., 7-
30 days after the end of treatment). Direct medical costs (USD, 2011 values) were 
calculated from the health care resources used, including study medication, 
hospitalization, mechanical ventilation, and dialysis. Nonparametric 
bootstrapping was conducted to calculate confidence intervals (CI) for costs, 
efficacy, and incremental cost-effectiveness ratios (ICER). One-way sensitivity 
analyses were conducted to evaluate the uncertainty and cost drivers. RESULTS: 
Data from 391 patients (186 linezolid, 205 vancomycin) were analyzed. A greater 
proportion of linezolid patients achieved treatment success versus vancomycin 
patients [mean (95% CI)]: 55% (48.3%-61.9%) versus 45% (38%-52.3%). Total costs 
per linezolid patient were $48,929 ($45,375-$52,483) compared to $46,665 
($43,201-$50,128) per vancomycin patient. The point estimate for the ICER of 
linezolid versus vancomycin was $16,516. The median ICER from bootstrapping 
was $16,219 (95% percentile: $100,487). Of the 10,000 bootstrap simulations, 73% 
had greater efficacies and higher costs (positive ICERs) for linezolid, 24% had 
greater efficacies and lower costs for linezolid (linezolid dominated vancomycin), 
and <2% had greater efficacies and lower costs for vancomycin (vancomycin 
dominated linezolid). Key cost drivers included number of ICU and general ward 
days in each treatment group. Addition of empirical treatment had a relatively 
small impact on ICER. CONCLUSIONS: In this clinical trial population, linezolid 
appears to be cost-effective compared to vancomycin in treating patients with 
nosocomial pneumonia due to MRSA.  
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OBJECTIVES: Posaconazole has shown superior clinical efficacy than 
Fluconazole/Itraconazole (FLU/ITRA) in the prevention of invasive fungal 
infections (IFIs) among patients with neutropenia resulting from chemotherapy 
for acute myelogenous leukemia (AML) or the myelodysplastic syndrome (MDS). 
Previous study has shown that Posaconazole is cost-effective versus FLU/ITRA in 
the 2007 U.S. health care setting.To reflect the changes in health care cost and 
the changes in drug prices, the study aims to provide an update on the cost-
effectiveness of Posaconazole in the current U.S. health care setting. METHODS: 
A previously published (O’Sullivan et.al., VIH 2009) cost effectiveness model was 
used to assess the cost-effectiveness of posaconazole versus FLU/ITRA in the 
prevention of IFIs among patients with neutropenia resulting from 
chemotherapy for AML or MDS. Drug efficacy, mortality related to IFIs and death 
from other causes, were all estimated using data from a randomized clinical trial 
(Cornely et.al., NEJM 2007). IFI treatment costs were inflation-adjusted over last 6 
years (2007-2012) and drug costs were based on 2012 IMS data. RESULTS: Trial 
data estimates the probability of an IFI over 100 days of follow-up while on 
Posaconazole to be lower than FLU /ITRA (0.05 vs. 0.11).The duration of treatment 
on Posaconazole is 25 days compared to 29 days with FLU or ITRA. Total costs of 
prophylaxis with FLU /ITRA and posaconazole is $5,293 and $5,859 respectively. 
The incremental cost-effectiveness ratios (ICER) for Posaconazole versus 
FLU/ITRA are estimated to be $8,805 per IFI avoided and $8,439 per life-year 
saved. CONCLUSIONS: Posaconazole is cost-effective to FLU or ITRA in the 
prevention of IFIs among neutropenic patients with AML and MDS in the current 
U.S. health care setting.  
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OBJECTIVES: Several studies have shown rotavirus vaccine is cost effective in 
low and middle income countries. Despite this, competing choices of rotavirus 
vaccines make the selection of either vaccine difficult for health decision-makers 
in low resource settings. The objective of this study is to assess cost 
effectiveness of the monovalent (MNV) and pentavalent (PTV) rotavirus vaccines 
on children mortality in 116 low and middle income countries that represent 
~99% of rotavirus mortality. METHODS: A decision economic model was built to 
estimate the effect of MNV or PTV vaccination. Inputs were gathered from 
international databases, previous research and a systematic review of MNV and 
PTV vaccine effectiveness. Outcomes were reported in terms of cost per 
disability-adjusted life-year (DALY) averted, comparing no vaccination being 
implemented on selected countries for the year 2010 with either MNV or PTV 
introduction. Costs were expressed in 2010 international dollars. RESULTS: Low 
and middle income countries would have had 601,511 deaths in 2010, if rotavirus 
vaccine would not have been used. Under no vaccine scenario, 139 DALYs per 
1000 children, 1.57 million inpatient and 9.17 million outpatient cases would 
occur every year. MNV would avert 53.3% of rotavirus-related deaths, and PTV 
57.9%. MNV and PTV were highly cost effective worldwide, according to WHO 
criteria (less than per capita gross domestic product). I$143 cost per DALY for 
MNV versus I$152 cost per DALY for PTV. Uncertainty was lower in low income 
countries. CONCLUSIONS: Rotavirus vaccine is cost-effective in all analyzed 
countries. Despite cost effectiveness analysis is a useful tool for decision making 
in middle income countries, for low income countries health-decision makers 
should also assess the impact of introducing either vaccine on local resources, 
and budget impact analysis of vaccination.  
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OBJECTIVES: Aspergillosis is the second cause of invasive fungal infections with 
high mortality rates. The objective of this research is to evaluate the cost-
effectiveness of amphotericin B(AB) 1.5mg/kg/day, amphotericin B liposomal(AL) 
3mg/kg/day, caspofungin(CA) 50mg/day, voriconazol 8mg/kg/day(VO) including 
maintenance oral Voriconazol 400mg/day scheme in the treatment of 
aspergillosis under the Brazilian private health care system perspective. 
METHODS: A decision tree model was built considering sequential treatments, 
from which patients could respond to one initial treatment and continue to a 
maintenance phase of the same medication, or do not respond due to either 
inefficacy or adverse events and switch treatments with assumed equal chance 
to use one of the other options. Effectiveness measures were mortality, clinical 
response and days of hospitalization, calculated by indirect comparison of a 
literature systematic review. Only direct costs were considered, and were 
obtained from CFM/CBHPM2010 for medical procedures, MOH/CMED 
December2012 price list for medications, and BRASINDICE for materials. Values 
were represented in 2012USD. A time horizon no longer than 4 weeks was 
considered, thus discounting was not applied. One-way sensitivity analysis 
considered de-hospitalization in maintenance phases while using oral 
voriconazol. RESULTS: Clinical response rates were 36.40%(AB), 34.60%(AL), 
34.20%(CA), 56.67%(VO), mortality rates were 50.90%(AB), 48.70%(AL), 44.70%(CA), 
34.10%(VO) and hospitalization days were 26.35(AB), 24.68(AL), 25.33(CA), 
22.55(VO). Expected treatment costs were US$33,838.33(AB), US$71,186.24(AL), 
US$46,223.28(CA) and US$36,255.09(VO). Considering AB as the baseline for cost-
effectiveness, VO presented an incremental cost-effectiveness ratio(ICER) of 
26,723.07 while other options were dominated with higher costs and lower 
effectiveness. If de-hospitalization was considered, VO would sum 14.62 
hospitalization days, treatment cost of US$32,755.71 and an ICER of US$9,459.23. 
CONCLUSIONS: Assuming a willingness to pay of US$32,621.93 (3 times the 
